Meet ‘Massive Bio’, An AI-Powered Oncology Platform That Connects Patients To Clinical Trials While Enabling Pharma To Get Access To Patients

The number of people diagnosed with cancer increases every year. Due to a dysfunctional healthcare system, it is pretty challenging for these individuals to find the appropriate treatments. There has always been a gap between patients and clinical trials and treatments.

Massive Bio is bridging the gap between patients and clinical trials using their AI-powered oncology platform by connecting them with each other while enabling pharma access to patients. With a focus on oncology and extremely innovative data, technology, and services in a fully broken clinical trial enrollment value chain, Massive Bio claims to be the only business on the market offering patient identification, pre-screening, and concierge enrollment enablement at the same time.

It offers a free cancer clinical trial matching on its website, where one can fill out a quick online assessment, and Massive Bio provides them with a detailed list of cancer clinical trials near them. The user does not have to travel to the clinical trial site until the enrollment process is complete. 

Massive Bio wants to use its AI and patient-centric concierge services at scale to reach cancer patients around the world and accelerate the oncology research and development infrastructure. There are a lot of active cancer clinical trials worldwide, whereas there are very few biomarkers and precision oncology molecules. With the aid of technology, Massive Bio aims to give every cancer patient access to clinical trials, regardless of their location or financial condition. 

The New York-based startup has raised $9 million in a Series A funding round. The round was co-led by Revo Capital and Kenan Turnacioglu, Chair of Board of Directors PaigeAI. The funding also saw additional participation from DEG – Deutsche Investitions- und Entwicklungsgesellschaft mbH, the German Development Finance Institution.

With the help of this funding, Massive Bio plans to expand its operations across the globe, invest in marketing, and introduce more innovative solutions.



Consultant Intern: Currently in her third year of B.Tech from Indian Institute of Technology(IIT), Goa. She is an ML enthusiast and has a keen interest in Data Science. She is a very good learner and tries to be well versed with the latest developments in Artificial Intelligence.

🐝 Join the Fastest Growing AI Research Newsletter Read by Researchers from Google + NVIDIA + Meta + Stanford + MIT + Microsoft and many others...